不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Monitoring malignant T-cell clones by direct TCR expression assay in patients with leukemic cutaneous T-cell lymphoma during extracorporeal photopheresis.
Monitoring malignant T-cell clones by direct TCR expression assay in patients with leukemic cutaneous T-cell lymphoma during extracorporeal photopheresis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的结果表明,DTEA 通过检测克隆性 TCR-Vα和 TCR-Vβ使用,能够有效评估恶性 T 细胞克隆。通过提供 TCR 库的全局视图,DTEA 还可能帮助我们理解恶性 T 细胞的起源和 CTCL 的发病机制。
准确评估白血病性皮肤T细胞淋巴瘤(L-CTCL)患者中的恶性T细胞克隆对于诊断、治疗和疾病监测至关重要。尽管已报道了多种定量恶性T细胞克隆的方法,但目前尚无一种具有广泛覆盖且成本效益高的检测方法。我们报告了一种基于NanoString-nCounter技术的直接TCR表达检测(DTEA),该检测此前被开发用于在过继免疫治疗后定量TCR-Vα和TCR-Vβ的使用情况。本研究旨在测试DTEA在评估L-CTCL患者恶性T细胞克隆中的有效性。
从开始体外光分离置换术(ECP)前(n = 15)以及治疗期间3个月和6个月时(n = 12)的患者外周血单个核细胞中提取的总RNA用于DTEA,使用针对45个TCR-Vα和46个TCR-Vβ家族成员的定制探针。
在基线时,DTEA在全部15例患者(100%)中检测到TCR-Vβ克隆,而流式细胞术在13例患者中的9例(69.2%)检测到TCR-Vβ克隆。除主要TCR-Vβ克隆外,DTEA还在15例患者中的8例(53.3%)中检测到额外的TCR-Vβ克隆。此外,DTEA同时识别了克隆性TCR-Vα的使用,这使我们能够配对恶性T细胞的TCR-Vα和TCR-Vβ使用,并识别多样化的克隆型。克隆性TCR-Vβ和TCR-Vα使用的相对频率随治疗的变化与患者的临床反应一致。
Total RNAs extracted from peripheral blood mononuclear cells of patients before starting extracorporeal photopheresis (ECP) (n = 15) and during therapy at 3 months and 6 months (n = 12) were used for DTEA, with customized probes for 45 TCR-Vα and 46 TCR-Vβ family members.
At baseline, DTEA detected TCR-Vβ clones in all 15 patients (100%) compared to flow cytometry that detected TCR-Vβ clones in 9 of 13 patients (69.2%). In addition to predominant TCR-Vβ clones, DTEA also detected additional TCR-Vβ clones in 8 of 15 patients (53.3%). Furthermore, DTEA simultaneously identified clonal TCR-Vα usages, which allowed us to pair TCR-Vα and TCRVβ usages by malignant T-cells and identify diversified clonotypes. Changes in the relative frequencies of clonal TCR-Vβ and TCRVα usages over therapy were consistent with patients' clinical responses.
Our results indicate that DTEA can effectively assess malignant T-cell clones by detecting clonal TCR-Vα and TCR-Vβ usages. By providing a global view of TCR repertoires, DTEA may also help us understand the origin(s) of malignant T-cells and pathogenesis of CTCL.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。